Objectives: This study aimed to investigate the relation between ApoE gene polymorphisms and major adverse cardiovascular events (MACE) in patients with acute coronary syndrome (ACS) during a 6-month follow-up. Methods: From October 2016 to July 2017, 211 patients were admitted to a cardiology clinic with a diagnosis of ACS. Blood samples were obtained from all patients on the first day. The primary end point was a 6-month incidence of MACE. ApoE gene polymorphism was genotyped by real-time PCR using TaqMan® SNP Genotyping Assay. Results: The patients with the E4 allele were associated with higher low-density lipoprotein (LDL) cholesterol and total cholesterol (TC) levels compared with the patients without the E4 allele (p = 0001 and p = 0.001). The patients with the E4 allele were associated with a higher rate of MACE compared with the patients without the E4 allele (ApoE4 allele(+) 23.1% vs. ApoE4 allele(−) 9.3%; p = 0.03). Multivariable analysis suggested that E4 allele carriers showed an 85% risk increment of 6-month MACE (odds ratio 2.48, 95% confidence interval 2.37–5.95; p = 0.01). Conclusions: The trial shows that E4 allele carriers were correlated with not only higher LDL cholesterol and TC levels, but also with a higher incidence of MACE during a 6-month follow-up.

Keywords:
Apolipoprotein E, Polymorphism, Major adverse cardiovascular events, Acute coronary syndrome
1.
Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, et al: Heart disease and stroke statistics – 2017 update: a report from the American Heart Association. Circulation 2017; 135:e146–e603.
2.
Liu R, Lyu SZ, Zhao GQ, Zheng W, Wang X, Zhao XD, Zhou SH, Zhen L, Nie SP: Comparison of the performance of the CRUSADE, ACUITY-HORIZONS, and ACTION bleeding scores in ACS patients undergoing PCI: insights from a cohort of 4,939 patients in China. J Geriatr Cardiol 2017; 14: 93–99.
3.
Anoop S, Meena MK, Luthra K: Apolipoprotein E polymorphism in cerebrovascular and coronary heart diseases. Indian J Med Res 2017; 132: 363–378.
4.
Atis O, Sahin S, Ceyhan K, Ozyurt H, Akbas A, Benli I: The distribution of apolipoprotein E gene polymorphism and apolipoprotein E levels among coronary artery patients compared to controls. Eurasian J Med 2016; 48: 90–94.
5.
Karahan Z, Uğurlu M, Uçaman B, Uluğ AV, Kaya İ, Çevik K, Öztürk Ö, Iyem H: Relation between apolipoprotein E gene polymorphism and severity of coronary artery disease in acute myocardial infarction. Cardiol Res Pract 2015; 2015: 363458.
6.
El-Lebedy D, Raslan HM, Mohammed AM: Apolipoprotein E gene polymorphism and risk of type 2 diabetes and cardiovascular disease. Cardiovasc Diabetol 2016; 15: 12.
7.
Heidari MM, Foruzannia SK, Khatami M, Hadadzadeh M, Meybodi ME: Apolipoprotein E gene polymorphism in Iranian coronary atherosclerosis patients candidate for coronary artery bypass graft. Iran J Basic Med Sci 2013; 16: 841–844.
8.
Eagle KA, Lim MJ, Dabbous OH, Pieper KS, Goldberg RJ, Van de Werf F, Goodman SG, Granger CB, Steg PG, Gore JM, Budaj A, Avezum A, Flather MD, Fox KA: A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. J Am Med Assoc 2004; 291: 2727–2733.
9.
Machal J, Vasku A, Hlinomaz O, Linhartova P, Groch L, Vitovec J: Apolipoprotein E polymorphism is associated with both number of diseased vessels and extent of coronary artery disease in Czech patients with CAD. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2012; 156: 151–158.
10.
Zende PD, Bankar MP, Kamble PS, Momin AA: Apolipoprotein E gene polymorphism and its effect on plasma lipids in arteriosclerosis. J Clin Diagn Res 2013; 7: 2149–2152.
11.
Grammer TB, Hoffmann MM, Scharnagl H, Kleber ME, Silbernagel G, Pilz S, Tomaschitz A, Lerchbaum E, Siekmeier R, März W: Smoking, apolipoprotein E genotypes, and mortality (the Ludwigshafen RIsk and Cardiovascular Health study). Eur Heart J 2013; 34: 1298–1305.
12.
Zhang MD, Gu W, Qiao SB, Zhu EJ, Zhao QM, Lv SZ: Apolipoprotein E gene polymorphism and risk for coronary heart disease in the chinese population: a meta-analysis of 61 studies including 6,634 cases and 6,393 controls. PLoS One 2014; 64:e95463.
13.
Yin YW, Sun QQ, Zhang BB, Hu AM, Liu HL, Wang Q, Hou ZZ: Association between apolipoprotein E gene polymorphism and the risk of coronary artery disease in Chinese population: evidence from a meta-analysis of 40 studies. PLoS One 2013; 8:e66924.
14.
Chotechuang Y, Phrommintikul A, Muenpa R, Patumanond J, Chaichuen T, Kuanprasert S, Thanachikun N, Benjanuwatra T, Sukonthasarn A: The prognostic utility of GRACE risk score in predictive cardiovascular event rate in STEMI patients with successful fibrinolysis and delay intervention in non PCI-capable hospital: a retrospective cohort study. BMC Cardiovasc Disord 2016; 16: 212.
15.
Bekler A, Altun B, Gazi E, Temiz A, Barutçu A, Güngör Ö, Özkan MT, Özcan S, Gazi S, Kırılmaz B: Comparison of the GRACE risk score and the TIMI risk index in predicting the extent and severity of coronary artery disease in patients with acute coronary syndrome. Anatol J Cardiol 2015; 15: 801–806.
16.
Fox KAA, Fitzgerald G, Puymirat E, Huang W, Carruthers K, Simon T, Coste P, Monsegu J, Gabriel Steg P, Danchin N, Anderson F: Should patients with acute coronary disease be stratified for management according to their risk? Derivation, external validation and outcomes using the updated GRACE risk score. BMJ Open 2014; 4:e004425.
17.
Suh Y J, Han K, Chang S, Kim JY, Im DJ, Hong YJ, Lee HJ, Hur J, Kim YJ, Choi BW: SYNTAX score based on coronary computed tomography angiography may have a prognostic value in patients with complex coronary artery disease: an observational study from a retrospective cohort. Medicine 2017; 96:e7999.
18.
Cuenza L, Collado MP, Ho Khe Sui J: Global risk score and clinical SYNTAX score as predictors of clinical outcomes of patients undergoing unprotected left main percutaneous catheter intervention. Cardiol Res 2017; 8: 312–318.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.